Merck donates its ebola vaccine

Article Excerpt

MERCK & CO. INC., $99.93, is a #1 buy for 2022. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (www.merck.com; Shares outstanding: 2.5 billion; Market cap: $252.5 billion; Dividend yield: 2.8%) now plans to produce and donate its investigational Sudan ebola virus vaccine to a global non-profit organization’s research program in Uganda. The East African nation currently facing an outbreak of the disease. The investigational vaccine that will be donated to the International AIDS Vaccine Initiative (IAVI) is similar to Merck’s Ervebo vaccine; it is approved against the Zaire ebola virus strain. IAVI aims to address urgent global health challenges. Merck & Co. is a #1 buy for 2022. 2022. …